CUMULATIVE INDEX Volume 1, Numbers 1-12, Pages 1-144 June 1999May 2000
CUMULATIVE INDEX Volume 1, Numbers 1-12, Pages 1-144 June 1999May 2000
A
ablational therapies, hepatic tumors, 8:85
angiogenesis, matrix metalloproteinase, 1:9
apoptosis breast cancer, 2:17 p53-dependent, 9:105 phospholipase A2, 6:69
B
biomarkers, DNA adducts, 3:31
bisphosphonates, cancer, 1:6
bladder cancer, N-acetyltransferase 2, 10:117
breast cancer apoptosis, 2:17 molecular markers, 7:75 paracrine regulation, 11:125
C
cancer biomarkers, DNA adducts, 3:31
cancer immunity, T cell, 11:129
cancer, high-dose chemotherapy, 7:78, 8:93
cell cycle arrest, prostate cancer, 2:17
cell cycle regulation, 10:111
chemotherapy and radiation, pancreatic cancer, 3:25
chemotherapy, high-dose, 7:78, 8:93
cholangiocarcinoma, cytokines, 12:141
colon cancer, colitis, 4:43
colorectal cancer, cyclooxygenase-2, 6:67 juvenile polyposis, 1:8
copper, liver cancer, 4:45
cyclooxygenase-2, colorectal cancer, 6:67
cytokines, cholangiocarcinoma, 12:141
D
dendritic cells, prostate cancer, 8:89
DNA adducts, biomarkers for cancer, 3:31
DNA methylation, cancer, 12:133
E
epidemiology, cancer, 2:13
esophageal cancer iron, 3:33 photodynamic therapy, 1:2
F
fluorescence bronchoscopy, lung cancer, 5:56
follicular lymphoma vaccine, 9:97
G
gender, lung cancer, 11:121
gene therapy, lung cancer, 1:1
gene, TbR-I(6A), 10:114
genetic susceptibility, head and neck cancer, 12:136
genomic instability, 7:73
glucose, malignant tissues. 5:51
H
head and neck cancer, genetic susceptibility, 12:136
hepatic tumors, ablational therapies, 8:85
hormone, steroid, 9:100
hypoxia, cancer cells, 1:11
I
iron, esophageal cancer, 3:33
L
liposomes, stealth, 6:65
liver cancer, copper, 4:45
lung cancer fluorescence bronchoscopy, 5:56 gender, 11:121 gene therapy, 1:1 photodynamic therapy, 1:2
lymphoma vaccine, 9:97
M
malignancies, secondary, and radiation exposure, 6:61
malignant tissues, glucose, 5:51
malignant transformation, 5:49
matrix metalloproteinase, angiogenesis, 1:9
melanoma, tumor vaccines, 4:37
metalloproteinases, tissue inhibitors, 8:91
MGI-114, prostate cancer, 4:41
microarray analysis, prostate cancer, 9:103
molecular markers, breast cancer, 7:75
N
N-acetyltransferase-2, bladder cancer, 10:117
NIH, peer review process, 5:59
nuclear matrix proteins, 2:15
P
pancreatic cancer, chemotherapy and radiation, 3:25
paracrine regulation, breast cancer, 11:25
peer review process, NIH, 5:59
phospholipase A2, apoptosis, 6:69
photodynamic therapy, lung cancer, 1:2
polyamines, prostate cancer, 11:128
polyposis, colorectal cancer, 1:8
prostate cancer cell cycle arrest, 2:17 dendritic cells, 8:89 MGI-114, 4:41 microarray analysis, 9:103 polyamines, 11:128 telomerase, 5:54
prostate, stromal-epithelial interactions, 3:28
proteins, nuclear matrix, 2:15
R
radiation and chemotherapy, pancreatic cancer, 3:25
radiation exposure, secondary malignancies, 6:61
renal cell carcinoma, telomerase, 5:54
RNA vaccine, 10:109
S
stealth liposomes, 6:65
steroid hormone receptor action, 9:100
T
T cell, cancer immunity, 11:129
telomerase, prostate and renal cell carcinoma, 5:54
V
vaccine follicular lymphoma, 9:97 RNA, 10:109 melanoma, 4:37
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.